Valuation : Exelixis, Inc.

Market Cap 13.91B 11.98B 11.34B 10.28B 19.29B 1,328B 19.39B 135B 51.81B 676B 52.22B 51.08B 2,136B P/E 2026 *
17.3x
P/E 2027 * 14.3x
Enterprise Value 13.16B 11.34B 10.74B 9.73B 18.26B 1,257B 18.35B 128B 49.04B 640B 49.43B 48.34B 2,021B EV / Sales 2026 *
5.16x
EV / Sales 2027 * 4.24x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-2.28%
1 week-4.90%
Current month+2.71%
1 month+11.39%
3 months+5.63%
6 months+36.31%
Current year+28.04%
1 week 54.54
Extreme 54.545
59.41
1 month 50.02
Extreme 50.02
59.72
Current year 39.71
Extreme 39.71
59.72
1 year 33.76
Extreme 33.755
59.72
3 years 18.64
Extreme 18.64
59.72
5 years 14.87
Extreme 14.87
59.72
10 years 10.04
Extreme 10.04
59.72
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-4.90%+43.35%+154.05% 13.91B
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.50%-3.14%+31.92%+238.13% 28.43B
Weighted average by Cap. -0.64%-2.93%+31.85%+169.84%

Financials

2026 *2027 *
Net sales 2.55B 2.2B 2.08B 1.89B 3.54B 244B 3.56B 24.73B 9.51B 124B 9.59B 9.38B 392B 2.9B 2.5B 2.37B 2.14B 4.02B 277B 4.04B 28.1B 10.8B 141B 10.89B 10.65B 445B
Net income 821M 707M 670M 607M 1.14B 78.4B 1.14B 7.95B 3.06B 39.89B 3.08B 3.01B 126B 1.01B 872M 826M 749M 1.4B 96.71B 1.41B 9.81B 3.77B 49.2B 3.8B 3.72B 155B
Net Debt -744M -641M -607M -551M -1.03B -71.12B -1.04B -7.21B -2.77B -36.18B -2.8B -2.73B -114B -1.62B -1.4B -1.32B -1.2B -2.25B -155B -2.26B -15.72B -6.05B -78.87B -6.09B -5.96B -249B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-09-11 $56.12 -2.28% 2,916,863
26-09-10 $57.43 -1.54% 1,789,572
26-09-09 $58.33 +1.14% 1,770,279
26-09-08 $57.67 -2.27% 2,538,923
26-09-04 $59.01 -0.20% 1,580,988
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
56.12USD
Average target price
53.69USD
Spread / Average Target
-4.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!